Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...130131132133134135136137138139140...170171»
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg.
    Journal:  Advances in Antithrombotic Therapy. (Pubmed Central) -  Dec 8, 2019   
    However, this benefit comes at the cost of increased bleeding albeit not fatal bleeding. To overcome this problem, the second advance is the identification of factor XI as a target for new anticoagulants that are potentially safer than those currently available.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca, enoxaparin sodium / Generic mfg.
    Review, Journal:  Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. (Pubmed Central) -  Dec 8, 2019   
    In the present review, we identified articles via PubMed using the combined keywords andexanet alfa, apixaban, enoxaparin, edoxaban, and rivaroxaban...The use of andexanet alfa requires close monitoring for signs and symptoms of thromboembolic events, ischemic events, and cardiac arrest. Furthermore, anticoagulation should be resumed following the administration of andexanet alfa as soon as medically appropriate.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Clinical, Journal:  A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs. (Pubmed Central) -  Dec 6, 2019   
    The RIV appeared well tolerated with one dog having one episode of vomiting on day 4 but otherwise no other side effects were identified clinically or on recheck blood work. The results of this study suggests that RIV at a dose of 1 mg kg orally once daily is safe and well tolerated but does not cause a significant prolongation of PT, aPTT or TEG parameters.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Trial completion date:  RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding (clinicaltrials.gov) -  Dec 5, 2019   
    P2/3,  N=50, Recruiting, 
    DOACs can be effectively and safely used in VTE patients with gynecological cancers. Trial completion date: Dec 2025 --> Dec 2026
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Rivaroxaban polymeric amorphous solid dispersions: moisture-induced thermodynamic phase behavior and intermolecular interactions. (Pubmed Central) -  Nov 29, 2019   
    In addition, molecular dynamics (MD) simulations were employed in order to interpret the observed differences in physical stability. Results, which were verified via differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR), suggested the formation of similar intermolecular interactions in all cases, indicating that the interaction with moisture water plays a more crucial role in ASD physical stability compared to the formation of intermolecular interaction between ASD components.
  • ||||||||||  Clinical, Observational data, Journal:  Patients' Perception of Newly Initiated Oral Anticoagulant Treatment for Atrial Fibrillation: an Observational Study. (Pubmed Central) -  Nov 28, 2019   
    Results, which were verified via differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR), suggested the formation of similar intermolecular interactions in all cases, indicating that the interaction with moisture water plays a more crucial role in ASD physical stability compared to the formation of intermolecular interaction between ASD components. No abstract available
  • ||||||||||  lamotrigine liquid oral suspension / OWP Pharma, carbamazepine / Generic mfg., Trileptal (oxcarbazepine) / Novartis
    Prevalence of Concurrent Prescriptions for Oral Anticoagulants and Antiepileptic Drugs Among People with Epilepsy Between 2010-2016 (Hall E) -  Nov 28, 2019 - Abstract #AES2019AES_341;    
    The OACs included warfarin, as well as those DOACs that received regulatory approval during the study time frame (dabigatran, rivaroxaban, apixaban, and edoxaban)...These findings highlight the clinical significance of advancing understanding of interactions between EI-AEDs and OACs, given their potential impact on as much as 7.17% of PWE. In particular, further research into proposed interactions with DOACs appears warranted in light of rapid uptake of this form of anticoagulation within the population with epilepsy.
  • ||||||||||  carbamazepine / Generic mfg.
    Interactions Between Anticonvulsants and Novel Oral Anticoagulants: A Systematic Review (Hall E) -  Nov 28, 2019 - Abstract #AES2019AES_293;    
    Rationale Novel oral anticoagulant medications including dabigatran etexilate, rivaroxaban, apixaban and edoxaban provide safe and convenient alternative for the traditional anticoagulation with vitamin K antagonists and heparin derivatives...Carbamazepine, phenytoin, and phenobarbital were reported to interact with NOAC...These interaction lead to either decreased NAOC plasma levels or development of thrombotic events. Conclustions Providers should be familiar with potential clinically significant interactions between NOAC and anticonvulsants and be aware of the use of drug level measurements to manage patients receiving these agents.
  • ||||||||||  Clinical, Journal:  Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). (Pubmed Central) -  Nov 28, 2019   
    Guidelines recommend warfarin continuation rather than heparin bridging for pacemaker and defibrillator surgery, after the BRUISE CONTROL trial demonstrated an 80% reduction in device pocket haematoma with this approach...We randomly assigned patients with atrial fibrillation and CHA2DS2-VASc score ≥2, to continued vs. interrupted DOAC (dabigatran, rivaroxaban, or apixaban)...Complications were uncommon, and included one stroke and one symptomatic pericardial effusion in each arm. These results suggest that, dependent on the clinical scenario, either management strategy (continued DOAC or interrupted DOAC) might be reasonable, at least for patients similar to those enrolled in our trial.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Rivaroxaban administration after acute ischemic stroke: The RELAXED study. (Pubmed Central) -  Nov 27, 2019   
    For the prevention of recurrent attacks in acute IS patients with NVAF, it is feasible to start the administration of rivaroxaban within 14 days of onset. Rivaroxaban started within 3 days of onset may be a feasible treatment option for patients with a small or medium-sized infarction.
  • ||||||||||  meropenem / Generic Mfg., Daewon Pharmaceutical
    Portal and superior mesenteric vein thrombosis after acute intestinal infection: A Case Report () -  Nov 24, 2019 - Abstract #APDW2019APDW_1581;    
    CT scan is an accurate method with excellent sensitivity for the diagnosis of abdominal vein thrombosis, especially as clinical presentation is emergency but vague. Oral anticoagulant rivaroxaban is a reliable and safe treatment for abdominal vessel thrombosis.
  • ||||||||||  Review, Journal, HEOR:  Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review. (Pubmed Central) -  Nov 23, 2019   
    Direct oral anticoagulants (DOACs) are currently used for VTE treatment, and they offer more benefits over warfarin, despite being more expensive...The search identified 7 articles, all of which had dabigatran and rivaroxaban as comparators, 6 of which also included apixaban, and 2 of which also had edoxaban...One article reported that apixaban had the highest annual total medical cost differences of US$918 ppy compared to other DOACs. This systematic review demonstrates that apixaban is considered a cost-effective strategy for VTE treatment and prevention of recurrent VTE.
  • ||||||||||  rivaroxaban / Generic mfg.
    Clinical, Journal:  Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis. (Pubmed Central) -  Nov 23, 2019   
    We sought to estimate the proportion of medically ill patients in the United States who might qualify for extended thromboprophylaxis according to the criteria used in the Medically-Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous ThromboEmbolism Risk (MARINER) trial...The modified IMPROVE-VTE score classified 1 186 475 (64.1%) of these hospitalizations as occurring in moderate-risk and 407 095 (22.0%) in high-risk patients. This real-world study suggests a substantial proportion of acute medically ill patients might benefit from extended thromboprophylaxis using the modified IMPROVE-VTE score and clinical elements of the MARINER trial.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Review, Journal:  Prevention and Treatment of Cancer-Associated Venous Thromboembolism: a Review. (Pubmed Central) -  Nov 23, 2019   
    There is mounting evidence to support use of the direct oral anticoagulants for VTE in patients with cancer. Decisions on type and duration of anticoagulation in patients with cancer, either for primary or secondary prevention, should be made on a case-by-case basis with taking into account the individual patient bleeding and thrombotic risk.